N@N

Patient Home Monitoring (PHM) announces agreement with Dr. Dinesh Thakur, MD FACC as Supervising Physician

^{Published on 2010-07-22 04:06:05 - Market Wire}
 

SAN FRANCISCO, July 22 /CNW/ - Patient Home Monitoring (PHM) (TSXV:PHM), a company focused on in-home cardiology healthcare services, today announced an agreement with Dr. Dinesh Thakur, MD FACC, to serve as PHM's Supervising Physician. Dr. Thakur will work with PHM to ensure compliance with established policies and procedures, objectives, quality assurance programs, safety and environmental standards.

Dr. Thakur is a Fellow of the American College of Cardiologists and a Board Certified Cardiologist based in the San Francisco Bay area. Dr. Thakur is an expert and advocate in the field of anti-coagulation Patient Self Testing (PST). Dr. Thakur was recently a Principal Investigator in a clinical trial for a device seeking FDA approval in the in-home PST market. Dr. Thakur has over 20 years of experience in Cardiology and anti-coagulation management.

"Dr. Thakur provides PHM with a crucial focus on quality within our monitoring protocols," said Ed Berenblum, CEO of Patient Home Monitoring. "PHM is dedicated to providing the highest standard of service to both patients and referring physicians. With the addition of Dr. Thakur to our team, I am confident that our clinically focused service will be of the highest level of quality in the industry."

"PHM continues to add the tools necessary to build a world class business," Michael Dalsin, Chairman of Patient Home Monitoring said.

About PHM

PHM is a healthcare services company focused on providing in-home testing for patients on blood thinner medications such as Coumadin or warfarin. Medicare recently expanded reimbursement for in-home patient self testing (PST) of blood coagulation levels. PHM has a unique value proposition to cardiology groups that manage patients on blood thinners, focusing on systemization to enroll patients in PST. This unique, systemized approach creates an opportunity for physician groups to operate more efficiently, while providing a higher standard of care for patients.

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of PHM and anticipated events or results, are assumptions based on beliefs of PHM's senior management as well as information currently available to it. While these assumptions were considered reasonable by PHM at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue operations, decline of reimbursement rates, dependence on few payors, possible new drug discoveries, a novel business model, dependence on key suppliers, granting of permits and licenses in a highly regulated business, competition, low profit market segments as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

%SEDAR: 00008298E